Biodexa Pharmaceticals (NASDAQ:BDRX) — Market Cap & Net Worth
Market Cap & Net Worth: Biodexa Pharmaceticals (BDRX)
Biodexa Pharmaceticals (NASDAQ:BDRX) has a market capitalization of $726.11K ($726.11K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30872 globally and #6260 in its home market, demonstrating a 42.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biodexa Pharmaceticals's stock price $1.12 by its total outstanding shares 648314 (648.31K). Also see BDRX current and non-current assets for a full breakdown of the balance sheet.
Biodexa Pharmaceticals Market Cap History: 2015 to 2026
Biodexa Pharmaceticals's market capitalization history from 2015 to 2026. Data shows change from $648.31 Billion to $726.11K (-71.95% CAGR). Also see Biodexa Pharmaceticals cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Biodexa Pharmaceticals is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #911 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2881 of 3165 |
Weight: Biodexa Pharmaceticals's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biodexa Pharmaceticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biodexa Pharmaceticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Biodexa Pharmaceticals for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
114.01x
Biodexa Pharmaceticals's market cap is 114.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $648.31 Billion | $1.32 Million | -$6.16 Million | 490033.26x | N/A |
| 2017 | $648.31 Billion | $989.00K | -$11.71 Million | 655524.77x | N/A |
| 2018 | $200.98 Billion | $1.94 Million | -$10.37 Million | 103703.48x | N/A |
| 2019 | $89.38 Billion | $674.00K | -$10.09 Million | 132606.18x | N/A |
| 2020 | $48.49 Billion | $343.00K | -$22.19 Million | 141381.60x | N/A |
| 2021 | $27.23 Billion | $578.00K | -$5.46 Million | 47109.32x | N/A |
| 2022 | $5.11 Billion | $699.00K | -$7.66 Million | 7308.60x | N/A |
| 2023 | $43.44 Million | $381.00K | -$7.08 Million | 114.01x | N/A |
Competitor Companies of BDRX by Market Capitalization
Companies near Biodexa Pharmaceticals in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Biodexa Pharmaceticals to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biodexa Pharmaceticals by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Biodexa Pharmaceticals Historical Marketcap From 2015 to 2026
Between 2015 and today, Biodexa Pharmaceticals's market cap moved from $648.31 Billion to $ 726.11K, with a yearly change of -71.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $726.11K | -50.66% |
| 2025 | $1.47 Million | -43.95% |
| 2024 | $2.63 Million | -93.96% |
| 2023 | $43.44 Million | -99.15% |
| 2022 | $5.11 Billion | -81.24% |
| 2021 | $27.23 Billion | -43.85% |
| 2020 | $48.49 Billion | -45.74% |
| 2019 | $89.38 Billion | -55.53% |
| 2018 | $200.98 Billion | -69.00% |
| 2017 | $648.31 Billion | 0.00% |
| 2016 | $648.31 Billion | 0.00% |
| 2015 | $648.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Biodexa Pharmaceticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $726.11K USD |
| MoneyControl | $726.11K USD |
| MarketWatch | $726.11K USD |
| marketcap.company | $726.11K USD |
| Reuters | $726.11K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more